ScripRoche, Sarepta Therapeutics’ ex-US partner for the commercialization of Elevidys (delandistrogene moxeparvovec), has voluntarily and temporarily paused shipments of the Duchenne muscular dystrophy (DM
ScripRoche’s recent Phase III failure for its anti-ST2 monoclonal antibody, astegolimab, in chronic obstructive pulmonary disease (COPD) is a blow not just for the firm but also for the fledgling drug clas
ScripAstraZeneca is the latest large pharma company to announce a major manufacturing investment in the US as the Trump administration threatens to slap tariffs on imports. The drugmaker said July 21 that
ScripThe US Food and Drug Administration’s complete response letter for Replimune’s biologics license application for RP1 (vusolimogene oderparepvec), a novel oncolytic immunotherapeutic for the treatment